$9.11
+0.42 (+4.83%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SENS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 4 with posted results
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 14.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ROME GS System StudyNCT07518004Mean absolute relative difference (MARD) for paired sensor and reference measurements post-insertion.Open-label · Diagnostic | Not applicable | Recruiting | Device: Continuous Glucose Monitoring System | Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2 | 60 | Aug 2028 | ≤ 742 d | 2026-04-21 |
| Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement FeatureNCT07386340System agreement (15/15%, 20/20%, 30/30%, and 40/40%) for paired sensor FGM and reference measurements post-insertion for reference glucose values from 40-400 mg/dL.Open-label · Diagnostic | Not applicable | Recruiting | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 80 | Dec 2027 | ≤ 498 d | 2026-04-21 |
| Eversense® Non-adjunctive Use Post Approval StudyNCT04836546Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis eventsOpen-label · Other | Not applicable | Active, not recruiting | Device: Blood glucose meter, Eversense CGM System | Diabetes | 925 | 2026-03-31 | — | 2025-08-13 |
| Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced FeaturesNCT05131139Effectiveness Objective: To determine accuracy of the Eversense 524 CGM System and ROME CGM System.Open-label · Diagnostic | Not applicable | Unknown status | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 350 | 2025-03-30 | — | 2023-04-26 |
| Post Approval Study of the Eversense® Continuous Glucose MonitoringNCT03908125results2025-06-12The Long-term Safety of the Eversense CGM Systems Over Repeat Insertion and Removal Cycles in the Post-market Setting.Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Eversense® CGM System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 273 | 2024-02-01actual | — | 2025-06-12 |
| PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 DaysNCT03808376results2024-08-20Effectiveness Measure - Mean Absolute Relative Difference (MARD) for Paired CGM and Reference Glucose MeasurementsOpen-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Continuous Glucose Monitoring System | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 208 | 2020-05-08actual | — | 2024-08-20 |
| PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and AlgorithmNCT03251079results2024-02-12Accuracy of CGM System Through 90 Days Post-Insertion (MARD for Paired CGM and Reference Glucose Measurements)Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Continuous glucose monitoring system | Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 36 | 2018-02-01actual | — | 2024-02-12 |
| A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in CanadaNCT02933164CGM Relative Difference to Laboratory Reference reported as MARDOpen-label · Diagnostic | Not applicable | Unknown status | Device: Continuous Glucose Monitoring System | Diabetes Mellitus | 36 | Aug 2017 | — | 2017-05-22 |
| Home Use Sensor StudyNCT02932514Accuracy of Eversense CGM System for Arm and Abdomen Sensors compared to SMBG Meter as determined by Mean Absolute Relative Difference (MARD) calculations.Open-label · Diagnostic | Not applicable | Unknown status | Device: Eversense (Senseonics) Continuous Glucose Monitoring System | Diabetes Mellitus | 17 | Jul 2017 | — | 2017-05-22 |
| Evaluation of the Accuracy of an Implanted Glucose SensorNCT02647905results2018-06-06CGM Relative Difference to Laboratory Reference Reported as MARDOpen-label · Diagnostic | Not applicable | Completed | Device: Continuous Glucose Monitoring System | Diabetes Mellitus | 90 | Jul 2016actual | — | 2018-06-06 |
| PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose SensorNCT02154126Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%Open-label · Diagnostic | Not applicable | Completed | Device: Continuous Glucose Monitoring Device (Senseonics) | Diabetes Mellitus | 81 | Nov 2015actual | — | 2016-01-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19